CLINICAL_TRIALS
trial_result
· 2008-02-11
Clinical Trial Update: BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis [Phase 2]
Summary
A Phase 2 trial evaluating BHT-3009 immunotherapy for relapsing-remitting multiple sclerosis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayhill Therapeutics | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED